Printer Friendly

DRUG SCREENING SYSTEMS' PCP TEST CLEARED FOR MARKETING BY THE FDA

 DRUG SCREENING SYSTEMS' PCP TEST CLEARED FOR MARKETING BY THE FDA
 BLACKWOOD, N.J., July 14 /PRNewswire/ -- Drug Screening Systems, Inc. (NASDAQ: DRUG), announced today that its proprietary on-site screening test for PCP (phencyclidine) has been "cleared for marketing" by the U.S. Food and Drug Administration (FDA) and will be marketed, together with the company's other tests for drugs of abuse, in the U.S., Europe, South America and the Far East by Wells Fargo Investigative Services and other distributors.
 The 510(k) application the company submitted to the Fa. Results of the clinical evaluation indicated that, as with the company's tests for opiates, cocaine, methamphetamine and cannabinoid (marijuana) which were previously cleared for marketing by the FDA, the reliability and sensitivity of the company's test to detect PCP in human urine equaled or exceeded that of conventional laboratory screening tests.
 "The addition of a PCP test to our product line, which now encompasses five of the most common drugs of abuse, greatly enhances the products' marketability," Robert G. Wallace, president, said. "The initial reaction to this new test has been enthusiastic, and continues to fuel our optimism for the future," he added. "This was an outstanding achievement for our scientific staff, which completed the development of this test ahead of schedule. Additional tests for amphetamine and barbiturates are nearing completion, and we expect to make application to FDA for these additional tests within the next several months."
 Wells Fargo Investigative Services (a subsidiary of BPS Guard Services) and other distributors and sales agents market the company's full line of tests for use by business, law enforcement, government and criminal justice agencies, and healthcare professionals.
 Drug Screening Systems is a biochemical diagnostic company engaged in the development, manufacture and marketing of on-site screening tests for drugs of abuse. The company's products are currently sold in the U.S. and throughout Europe, South America and the Far East under the trademarks MACH IV (R) and microLINE (TM) SCREEN.
 -0- 7/14/92
 /CONTACT: Gary Nacht of Drug Screening Systems, 609-228-8500/
 (DRUG) CO; Drug Screening Systems, Inc. ST: New Jersey IN: HEA MTC SU:


SH-KD -- NY027 -- 9025 07/14/92 10:34 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1992
Words:362
Previous Article:/C O R R E C T I O N -- SHERWIN-WILLIAMS EARNINGS/
Next Article:IPL FILES APPLICATION TO REOPEN ITS SARNIA-MONTREAL PIPELINE
Topics:


Related Articles
U.S. DRUG TESTING RECEIVES FDA MARKETING APPROVAL
U.S. ALCOHOL TESTING SUBMITS NEW 510(k) APPLICATION TO FDA
U.S. DRUG TESTING INC. RECEIVES FDA MARKETING APPROVAL ON FLOW IMMUNOASSAY SYSTEM, MODEL 9000
COMPANY SUBMITS 510(k) APPLICATION TO FDA FOR PHENCYCLIDINE ASSAY
EDITEK RECEIVES SECOND VERDICT FDA PRE-MARKET CLEARANCE
FDA PANEL RECOMMENDS CLEARANCE OF STC TEST KITS AND PHARMCHEK(R) SWEAT PATCH
PARENT'S ALERT: WAR ON DRUGS TAKES POSITIVE TURN
EDITEK LAUNCHES EZ-SCREEN(R) PROFILE(TM) DRUGS OF ABUSE PRODUCT
EDITEK Receives FDA Pre-Market Clearance For EZ-SCREEN(R) PROFILE(TM) Drugs of Abuse Product

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters